Results of genome-wide CRISPR-Cas9 screens with the Avana sgRNA library in 341 cancer cell lines performed at the Broad Institute as part of the Cancer Dependency Map project. For the latest dataset a
Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy across multiple cancer types. However, only a fraction of patients respond to ICB. Here, we performed pooled mutagenic screening
